IRWD Stock Price - Ironwood Pharmaceuticals Inc. Cl A Stock Quote (U.S.: Nasdaq) - MarketWatch

After pressure from shareholders and an activist investor, Ironwood Pharmaceuticals will take the unusual step of separating from a unit developing drugs for rare diseases.

May. 1, 2018 at 9:45 p.m. ET
on The Wall Street Journal

Celebrating Failure in a Tough Drug Industry

Mar. 3, 2017 at 2:18 p.m. ET
on The Wall Street Journal

Valeant Looks to Show Steps Toward Normalcy

Jun. 4, 2016 at 5:30 a.m. ET
on The Wall Street Journal

Eight Biotechs to Outperform the Market

Jan. 8, 2015 at 8:24 a.m. ET
on Barron's

CFO Moves: Bluebird Bio, Social Reality, Primeline Energy Holdings

Nov. 10, 2014 at 4:23 p.m. ET
on The Wall Street Journal

Up and Down the Ladder: The Latest Comings and Goings at ICON, Ironwood and…

Sep. 5, 2014 at 8:59 a.m. ET
on The Wall Street Journal

In Drug Mergers, There's One Sure Bet: The Layoffs

Apr. 29, 2014 at 7:12 p.m. ET
on The Wall Street Journal

Biotech Bull-Run Versus Bubble

Apr. 8, 2014 at 10:47 a.m. ET
on Barron's

Stocks to Watch: Netflix, Coach, RadioShack

Apr. 23, 2013 at 9:54 a.m. ET
on The Wall Street Journal

MedAssets CEO Sells Near Share-Price Highs

Nov. 26, 2012 at 5:30 p.m. ET
on Barron's

Biotech Intarcia Raises $210 Million

Nov. 15, 2012 at 11:55 a.m. ET
on The Wall Street Journal

Big Pharma Picks for Q3 Earnings

Oct. 17, 2012 at 1:02 p.m. ET
on Barron's

Ironwood Shares Could Rebound

Sep. 4, 2012 at 10:41 a.m. ET
on Barron's

A.M. Vitals: Democrats Ready Response on Medicare

Aug. 31, 2012 at 8:17 a.m. ET
on The Wall Street Journal

FDA Approves Constipation Drug

Aug. 30, 2012 at 2:35 p.m. ET
on The Wall Street Journal

Large Stock Focus: Best Buy Shines, Banks Fall

Sep. 14, 2010 at 9:50 p.m. ET
on The Wall Street Journal

Large Stock Focus: Best Buy Shines, Banks Fall

Sep. 14, 2010 at 5:29 p.m. ET
on The Wall Street Journal

Venture Capitalists Enjoying More Deals, IPOs

May. 11, 2010 at 6:47 p.m. ET
on The Wall Street Journal

Ironwood Pharma Up Post-IPO; Imperial Capital Delayed

Feb. 3, 2010 at 1:42 p.m. ET
on The Wall Street Journal

Other News
Press Releases

Premarket analyst action - healthcare

May. 9, 2018 at 8:34 a.m. ET
on Seeking Alpha

Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, ...

Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, CytomX Therapeutics Inc, AnaptysBio Inc

May. 7, 2018 at 7:38 p.m. ET
on GuruFocus.com

10-Q: IRONWOOD PHARMACEUTICALS INC

May. 4, 2018 at 4:16 p.m. ET
on Edgar Online - (EDG = 10Q, 10K)

10-Q: IRONWOOD PHARMACEUTICALS INC

May. 4, 2018 at 4:16 p.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Barclays Keeps Their Hold Rating on Ironwood Pharma

In a report released yesterday, Geoff Meacham from Barclays maintained a Hold rating on Ironwood ...[...]

May. 3, 2018 at 10:12 a.m. ET
on SmarterAnalyst

Your Daily Pharma Scoop: IRWD Division, Jazz sNDA, Siga Adcomm

May. 3, 2018 at 8:00 a.m. ET
on Seeking Alpha

Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

May. 2, 2018 at 11:00 a.m. ET
on Zacks.com

Premarket analyst action - healthcare

May. 2, 2018 at 8:18 a.m. ET
on Seeking Alpha

Ironwood Will Separate From Its Rare-Disease Drug Unit After Pressure

After pressure from shareholders and an activist investor, Ironwood Pharmaceuticals will take the unusual step of separating from a unit developing drugs for rare diseases.

May. 1, 2018 at 9:45 p.m. ET
on The Wall Street Journal

Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD) and Allena Pharmaceuticals Inc (NASDAQ: ALNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just ...[...]

May. 1, 2018 at 7:19 p.m. ET
on SmarterAnalyst

Ironwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q1 2018 Results - Earnings Call Transcript

May. 1, 2018 at 4:13 p.m. ET
on Seeking Alpha

Ironwood Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides

May. 1, 2018 at 1:14 p.m. ET
on Seeking Alpha

Ironwood Pharma to split into two entities; shares down 6% premarket

May. 1, 2018 at 9:28 a.m. ET
on Seeking Alpha

Notable earnings before Tuesday’s open

Apr. 30, 2018 at 5:30 p.m. ET
on Seeking Alpha

OrphoMed's lead candidate Fast Track'd for IBS-D

Apr. 25, 2018 at 12:01 p.m. ET
on Seeking Alpha

Synergy Pharmaceuticals: Best Drug + Terrible Management = Terrible Investment

Apr. 23, 2018 at 2:30 p.m. ET
on Seeking Alpha

Ironwood investor Sarissa Capital to nominate board member

Apr. 9, 2018 at 3:18 p.m. ET
on Seeking Alpha

Ironwood Pharmaceuticals (IRWD) Presents At Barclays Global Healthcare Conference 2018 - Slideshow

Mar. 15, 2018 at 2:18 p.m. ET
on Seeking Alpha

Ironwood Pharmaceuticals (IRWD) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow

Mar. 12, 2018 at 12:43 p.m. ET
on Seeking Alpha

Key events next week - healthcare (continued #5)

Mar. 9, 2018 at 10:02 a.m. ET
on Seeking Alpha

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value

May. 9, 2018 at 8:30 a.m. ET
on BusinessWire - BZX

Oral Proteins and Peptides Market (3rd Edition), 2018-2030

May. 8, 2018 at 8:30 a.m. ET
on PR Newswire - PRF

Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals -- What Drives Growth in Today's Competitive Landscape

Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals -- What Drives Growth in Today's Competitive Landscape

May. 7, 2018 at 7:30 a.m. ET
on GlobeNewswire

Global Irritable Bowel Syndrome Treatment Market Competitive landscape: Novartis AG

May. 4, 2018 at 12:48 a.m. ET
on marketresearch.biz

Ireland : Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action

May. 3, 2018 at 7:59 p.m. ET
on Euclid Tenders Info

Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

May. 3, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Blog Exposure - Ironwood to Separate Its Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business

May. 3, 2018 at 7:50 a.m. ET
on ACCESSWIRE

Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action

May. 1, 2018 at 4:01 p.m. ET
on PR Newswire - PRF

Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call

Apr. 17, 2018 at 4:01 p.m. ET
on BusinessWire - BZX

Global Irritable Bowel Syndrome Treatment Market Opportunities 2018: Ironwood Pharmaceuticals , GlaxoSmithKline plc., Abbott Laboratories, Novartis AG, Ardelyx

Apr. 9, 2018 at 8:00 a.m. ET
on marketresearch.biz

Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital

Apr. 9, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

This Morning's Technical Outlook on Generic Drugs Stocks -- Ironwood Pharma, Pacira Pharma, pSivida, and Tetraphase Pharma

Mar. 21, 2018 at 6:10 a.m. ET
on PR Newswire - PRF

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

Mar. 5, 2018 at 4:01 p.m. ET
on BusinessWire - BZX

Analysis: Positioning to Benefit within Ironwood Pharmaceuticals, Altaba, The AES, PACCAR, NVR, and WPX Energy -- Research Highlights Growth, Revenue, and Consolidated Results

Mar. 5, 2018 at 7:41 a.m. ET
on GlobeNewswire

Blog Exposure - FDA Accepted Mallinckrodt's New Drug Application for Stannsoporfin for Severe Hyperbilirubinemia

Feb. 26, 2018 at 7:22 a.m. ET
on ACCESSWIRE

Today's Research Reports on Stocks to Watch: Ironwood Pharmaceuticals and Teva Pharmaceutical

Feb. 16, 2018 at 8:10 a.m. ET
on ACCESSWIRE

Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Akorn, Collegium Pharma, Horizon Pharma, and Ironwood Pharma

Feb. 2, 2018 at 6:25 a.m. ET
on PR Newswire - PRF

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call

Feb. 1, 2018 at 4:01 p.m. ET
on BusinessWire - BZX

Today's Research Reports on Trending Tickers: Aerie Pharmaceuticals and Ironwood Pharmaceuticals

Jan. 25, 2018 at 8:21 a.m. ET
on ACCESSWIRE

Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Jan. 16, 2018 at 8:30 a.m. ET
on BusinessWire - BZX

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 12 Full Ratings

BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Jan. 5, 2018 at 5:32 p.m. ET
on Benzinga.com

Could The Street Be Underappreciating The Ironwood Pharma Pipeline?

Nov. 27, 2017 at 1:31 p.m. ET
on Benzinga.com

Ironwood's Pipeline Needs Work, Analyst Downgrades

Jul. 21, 2017 at 10:48 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Progenics Pharmaceuticals Inc.	0.29%	$510.87M
Nektar Therapeutics	-1.00%	$13.37B
Cumberland Pharmaceuticals Inc.	-1.73%	$99.55M
AstraZeneca PLC ADR	0.34%	$89.71B
Synergy Pharmaceuticals Inc.	0.72%	$377.5M

Competitor Data Provided By

Dow	24,396.29	36.08	0.15%
S&P 500	2,680.21	8.29	0.31%
Nasdaq	7,280.67	13.77	0.19%
GlobalDow	3,059.89	12.34	0.40%
Gold	1,314.30	0.60	0.05%
Oil	70.90	1.84	2.66%

Ironwood Pharmaceuticals Inc. Cl A

$ 17.30

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Ironwood Pharmaceuticals downgraded to underweight at Morgan Stanley

Ironwood Pharma announces positive results in midstage trial of diabetes treatment

Ironwood Pharma shares jump 3.5% premarket

Ironwood Pharmaceuticals stock price target raised to $12 from $8 at UBS

Ironwood Pharmaceuticals downgraded to neutral from overweight at J.P. Morgan

Stocks

Columns

Authors

Topics

^$ 17.30